Payment overview · 2025
General Payments
$46,073.13
79 reported records · 24 companies
Healthcare provider profile · identity verified
Richard D Kim, M. D.
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · TAMPA, FL · NPI 1609810779
Verified facts
What the public records show
CMS Open Payments records show Richard D Kim, M. D. received $46,073.13 in general payments during 2025 across 79 reported records.
SERVIER PHARMACEUTICALS LLC accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabometyx, Lenvima.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lenvima by this doctor in 2024.
Exelixis Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABOMETYX as an associated drug or biological on 11749 records involving 4526 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Cabometyx by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $7,987.92 | 17.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $6,576.22 | 14.3% | 4 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $5,093.42 | 11.1% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $4,675.43 | 10.2% | 5 | 2025 |
| Partner Therapeutics, Inc. | Unresolved — no canonical attribution shown | $4,608.05 | 10.0% | 11 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $4,292.73 | 9.3% | 4 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $4,219.90 | 9.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $4,058.34 | 8.8% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $1,896.26 | 4.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $606.67 | 1.3% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $481.19 | 1.0% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $266.53 | 0.6% | 2 | 2025 |
| Intera Oncology, Inc | Unresolved — no canonical attribution shown | $257.87 | 0.6% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $163.63 | 0.4% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $136.11 | 0.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $135.75 | 0.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$125.00 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.23 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.96 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.97 | 0.2% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $64.42 | 0.1% | 1 | 2025 |
| Servier BioInnovation | Unresolved — no canonical attribution shown | $50.00 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.22 | 0.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.31 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $31,814.17 | 12 |
| Travel and Lodging | $5,732.03 | 13 |
| Food and Beverage | $4,185.17 | 50 |
| Honoraria | $3,300.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $974.76 | 2 |
| Education | $67.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $10,796.12 | 10 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $7,987.92 | 3 | 2025 |
Source payment records
|
|||||
| Bizengri Normalized: bizengri |
Drug | Partner Therapeutics, Inc. | $4,608.05 | 11 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $4,511.44 | 4 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $4,292.73 | 4 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $481.19 | 5 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $343.05 | 2 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $266.53 | 2 | 2025 |
Source payment records
|
|||||
| INTERA Normalized: intera |
Device | Intera Oncology, Inc | $257.87 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $191.34 | 6 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $163.63 | 1 | 2025 |
Source payment records
|
|||||
| General - Interventional Oncology Normalized: general interventional oncology |
Device | Boston Scientific Corporation | $135.75 | 1 | 2025 |
Source payment records
|
|||||
| Somatuline Depot Normalized: somatuline depot |
Drug | Ipsen Biopharmaceuticals, Inc | $129.51 | 1 | 2025 |
Source payment records
|
|||||
| SIGNIA Normalized: signia |
Device | Medtronic, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | PFIZER INC. | $124.08 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $117.23 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.97 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $67.00 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $64.42 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $51.58 | 1 | 2025 |
Source payment records
|
|||||
| S95031 Normalized: s95031 |
Drug | Servier BioInnovation | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $45.22 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABOMETYX cabometyx |
2025 | Cabometyx | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Lenvima lenvima |
2025 | Lenvima | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Exelixis Inc. Exact reporting entity; no affiliate inference |
2025 | CABOMETYX open payments reported associated product |
CMS Open Payments — General Payments 11749 supporting records · 4526 recipient NPIs · example record 1218789893 |
Cabometyx · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 61 | 26 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 14 |
| Lorazepam | Lorazepam | 29 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 12 | suppressed |
| Lenvima | Lenvatinib Mesylate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46,073.13 · 79 records | SERVIER PHARMACEUTICALS LLC | BENLYSTA, BRAFTOVI, Bizengri, CABOMETYX, General - Interventional Oncology, IMFINZI, INTERA, JEMPERLI, Lenvima, MEKTOVI, MI CANCER SEEK, OPDIVO, Onivyde, RETEVMO, S95031, SIGNIA, Somatuline Depot, Stivarga, TEVIMBRA, TUKYSA, Tibsovo, Vitrakvi, ZENPEP, ZIIHERA, ZYNYZ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabometyx play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Eisai Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error